1h Free Analyst Time
According to the recently published report 'Metabotropic Glutamate Receptor 5 - Drugs In Development, 2022'; Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 19 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.Speak directly to the analyst to clarify any post sales queries you may have.
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Metabotropic glutamate receptor 5 (mGluR5) is a G protein-coupled receptor. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol calcium second messenger system and generates a calcium activated chloride current. mGluR5 plays an important role in the regulation of synaptic plasticity and the modulation of the neural network activity.
The report 'Metabotropic Glutamate Receptor 5 - Drugs In Development, 2022' outlays comprehensive information on the Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 3, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Ophthalmology and Undisclosed which include indications Anxiety Disorders, Depression, Alzheimer's Disease, Blepharospasm, Fragile X Syndrome, Major Depressive Disorder, Pain, Parkinson's Disease, Schizophrenia, Substance (Drug) Abuse, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Cognitive Impairment, Dementia, DiGeorge Syndrome, Drug Addiction, Dyskinesia, Dystonia, Seizures, Spasmodic Torticollis (Cervical Dystonia), Stammering (Stuttering), Trigeminal Neuralgia (Tic Douloureux) and Unspecified.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)
- The report reviews Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Overview
- Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Companies Involved in Therapeutics Development
- Addex Therapeutics Ltd
- Allyx Therapeutics Inc
- Appello Pharmaceuticals Inc
- Bristol-Myers Squibb Co
- Hua Medicine Shanghai Ltd
- Laboratorio Farmaceutico CT Srl
- Lactocore Inc
- Nobias Therapeutics Inc
- Noema Pharma AG
- Novartis AG
- Park of Active Molecules
- Tempero Bio
- Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drug Profiles
- alloswitch-1 - Drug Profile
- Product Description
- Mechanism Of Action
- ALX-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AP-612 - Drug Profile
- Product Description
- Mechanism Of Action
- basimglurant - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BMS-952048 - Drug Profile
- Product Description
- Mechanism Of Action
- dipraglurant - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- dipraglurant ER - Drug Profile
- Product Description
- Mechanism Of Action
- dipraglurant IR - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GET-73 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- HTL-0014242 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LCGM-10 - Drug Profile
- Product Description
- Mechanism Of Action
- mavoglurant - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- mGLUR5 NAM - Drug Profile
- Product Description
- Mechanism Of Action
- NB-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PAM-12 - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Agonize mGluR5 for Schizophrenia - Drug Profile
- Product Description
- Mechanism Of Action
- VU-0092273 - Drug Profile
- Product Description
- Mechanism Of Action
- VU-0431316 - Drug Profile
- Product Description
- Mechanism Of Action
- VU-0467558 - Drug Profile
- Product Description
- Mechanism Of Action
- Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Dormant Products
- Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Discontinued Products
- Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Product Development Milestones
- Featured News & Press Releases
- Sep 06, 2022: Noema Pharma announces completion of enrollment in the Trigeminal Neuralgia Electronic Diary (TNED) validation study
- Jun 17, 2022: Addex terminates dipraglurant phase 2b/3 study in patients with dyskinesia associated with Parkinson’s disease due to slow recruitment rate
- May 27, 2022: Addex provides update on dipraglurant blepharospasm phase 2 feasibility clinical study
- Apr 13, 2022: Addex Therapeutics completes patient enrollment for dipraglurant blepharospasm phase 2 clinical study
- Feb 22, 2022: Noema Pharma announces first patient dosed in Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia
- Feb 14, 2022: Noema Pharma announces FDA Investigational New Drug Authorization for Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia
- Sep 29, 2021: Addex Therapeutics initiates phase 2 clinical study with Dipraglurant in blepharospasm
- Jul 07, 2021: Noema Pharma to host a key opinion leader webinar on seizures in tuberous sclerosis complex
- Jun 29, 2021: Addex Therapeutics initiates pivotal phase 2b/3 study with dipraglurant for dyskinesia associated with Parkinson’s Disease
- May 17, 2021: Addex’s Dipraglurant restores synaptic plasticity in models of Dystonia
- Mar 18, 2020: Addex Therapeutics delays start of Dipraglurant pivotal study and reporting 2019 full year audited results
- Jan 17, 2019: Experimental drug improves eye gaze behavior in fragile X syndrome
- Dec 13, 2018: Sosei Heptares starts new clinical development program - First subject dosed in Phase I study of HTL0014242, a selective mGlu5 negative allosteric modulator in development to treat psychiatric and neurological disorders
- Oct 18, 2017: Van Leeuwenhoeck Issues Initiation of Coverage Research Report on Addex Therapeutics and Estimated ADXN Share Price of CHF 11.5 per Share
- Feb 06, 2017: Addex's Clinical Programs and Discovery Platform Highlighted in Review of Allosteric Modulators for the Treatment of Neurodegenerative Diseases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Addex Therapeutics Ltd, 2022
- Pipeline by Allyx Therapeutics Inc, 2022
- Pipeline by Appello Pharmaceuticals Inc, 2022
- Pipeline by Bristol-Myers Squibb Co, 2022
- Pipeline by Hua Medicine Shanghai Ltd, 2022
- Pipeline by Laboratorio Farmaceutico CT Srl, 2022
- Pipeline by Lactocore Inc, 2022
- Pipeline by Nobias Therapeutics Inc, 2022
- Pipeline by Noema Pharma AG, 2022
- Pipeline by Novartis AG, 2022
- Pipeline by Park of Active Molecules, 2022
- Pipeline by Tempero Bio, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Addex Therapeutics Ltd
- Allyx Therapeutics Inc
- Appello Pharmaceuticals Inc
- Bristol-Myers Squibb Co
- Hua Medicine Shanghai Ltd
- Laboratorio Farmaceutico CT Srl
- Lactocore Inc
- Nobias Therapeutics Inc
- Noema Pharma AG
- Novartis AG
- Park of Active Molecules
- Tempero Bio
